N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

Sponsor: Sairam Parthasarathy • ClinicalTrials.gov ID: NCT07679282

Registry updated: 2026-10-19
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.

Interventions

  • Positive airway pressure (PAP) therapy (Device)
    Positive airway pressure delivered via a nasal or face mask while a patient sleeps to keep the airways open.
  • Sleep dental device (Device)
    An oral appliance worn during sleep to move the lower jaw forward, which tightens soft tissues and widens the airway to prevent sleep apnea.
  • Atomoxetine-oxybutynin (Drug)
    The combination of two medications (atomoxetine-oxybutynin) can reduce obstructive sleep apnea by increasing upper airway muscle activity.

Eligibility criteria

Inclusion Criteria: * Obstructive sleep apnea (AHI \>/= 5 per hour), diagnosed in the past 6 months * Two or more of the following symptoms: snoring, fragmented sleep, witnessed apneas, or daytime sleepiness * Willingness/ability to use any of the 3 treatments for OSA (PAP, dental device, or atomoxetine-oxybutynin) * Health insurance of any type Exclusion Criteria: * Prior treatment for OSA in past year * Central sleep apnea or narcolepsy * Contraindication for dental device (temporomandibular joint problems, severe periodontal disease, insufficient dentition) * Heart failure with reduced ejection fraction of \</= 45% * Active coronary artery disease (angina or infarction within 3 months of enrollment) * Current untreated depression * Untreated narrow angle glaucoma * Untreated hypothyroidism * Clinically significant gastric retention * Clinically significant urinary retention * History of liver disease * Seizure disorder * Pregnant or nursing, or plans to become pregnant within the year * Concomitant medication use that is incompatible with atomoxetine or oxybutynin * Participation in another clinical study with an investigational product

Conditions

Obstructive Sleep Apnea (OSA)

Locations

  • Banner University Medical Center Tucson — Tucson, Arizona, United States
  • Stanford Medical Center — Redwood City, California, United States
  • University of Miami Miller School of Medicine — Miami, Florida, United States
  • University of Maryland Baltimore — Baltimore, Maryland, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record